Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LLH1 CRISPR Activation Plasmid (h): sc-404079-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LLH1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- LLH1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by LLH1 CRISPR Activation Plasmid (h) and LLH1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PLOD1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LLH1 Antibody (B-5): sc-271640
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LLH1 CRISPR Activation Plasmid (h) | sc-404079-ACT | 20 µg | $397.00 |
Human PLOD1 encodes lysyl hydroxylase 1 (LLH1), an ER-resident Fe2+/2-oxoglutarate–dependent dioxygenase that hydroxylates lysine residues in procollagen, a prerequisite for stable intermolecular crosslinking and proper extracellular matrix assembly. By regulating collagen maturation, LLH1 influences matrix mechanics, cell–matrix signaling, and tissue remodeling processes that intersect with fibrosis-associated programs and wound repair. Altered PLOD1 activity perturbs collagen fibrillogenesis and basement membrane organization, and has been linked to connective tissue fragility phenotypes and broader matrix dysregulation observed in diverse pathological contexts. As a result, PLOD1/LLH1 is frequently investigated in studies of collagen biosynthesis, ER proteostasis, and ECM-driven modulation of cell behavior.
LLH1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PLOD1 expression without altering the underlying DNA sequence.
LLH1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PLOD1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PLOD1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous LLH1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PLOD1 locus and enabling the study of LLH1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of LLH1 pathway restoration in tumor cells with silenced or reduced PLOD1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.